12:00 AM
 | 
Aug 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Sovaprevir: Additional Phase IIa data

Data from 36 evaluable patients with chronic HCV genotype 1 infection in the second part of a double-blind, placebo-controlled, U.S. and Belgian Phase IIa trial showed that once-daily oral sovaprevir in combination with standard of care (SOC; peginterferon alfa-2a and ribavirin) for 12 weeks followed by SOC alone for an additional 12 weeks led to an SVR4, defined as undetectable HCV RNA levels (<25 IU/mL) 4 weeks after the end of treatment, in 90% of patients in the 200 mg sovaprevir arm, 85%...

Read the full 394 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >